SYHA1813

Kundenbewertung

Based on 1 Customer Validation

SYHA1813 is a blood-brain barrier-penetrant, orally effective dual VEGFR and CSF1R receptor tyrosine kinase inhibitor. SYHA1813 exhibits IC50 values of 2.8, 0.3, 4.3, and 19.3 nM against VEGFR-1, VEGFR-2, VEGFR-3, and CSF1R, respectively. SYHA1813 blocks VEGFR and CSF1R kinase activity, inhibits pro-tumor macrophage polarization and angiogenesis, and modulates the tumor immune microenvironment. SYHA1813 activates the ATM/CHK/P53 signaling pathway, impairs DNA damage repair, and induces G2/M phase arrest, apoptosis, and senescence. SYHA1813 also inhibits c-Kit and PDGFRα kinases. SYHA1813 can be used for research on glioblastoma, malignant meningioma, melanoma, and diffuse large B-cell lymphoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Reinheit : 99.46%
  • CAS. Nr.: 1807466-30-3
  • Formel: C25H19FN4O
  • Molecular Weight:410.44
  • Speicherung:

    4°C, protect from light

    * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

  • Biologische Aktivität
  • Chemical Information
  • Lösungsmittel & Löslichkeit
  • Protokoll
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

Angebot einholen Auf Lager

Other size
Angebot einholen
Please select quantity
Amount: USD 0.00